Meeting the "Go'' criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults
Publication
, Conference
Bekker, L-G; Laher, F; Moodie, Z; Tomaras, G; Grunenberg, N; Allen, M; Daniels, B; Innes, C; Mngadi, K; Malahleha, M; Gilbert, P; Michael, N ...
Published in: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
July 1, 2016
Duke Scholars
Published In
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
EISSN
1758-2652
Publication Date
July 1, 2016
Volume
19
Publisher
JOHN WILEY & SONS LTD
Related Subject Headings
- 4206 Public health
- 4202 Epidemiology
- 3202 Clinical sciences
- 1199 Other Medical and Health Sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Bekker, L.-G., Laher, F., Moodie, Z., Tomaras, G., Grunenberg, N., Allen, M., … McElrath, J. (2016). Meeting the "Go'' criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (Vol. 19). JOHN WILEY & SONS LTD.
Bekker, L. -. G., F. Laher, Z. Moodie, G. Tomaras, N. Grunenberg, M. Allen, B. Daniels, et al. “Meeting the "Go'' criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults.” In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, Vol. 19. JOHN WILEY & SONS LTD, 2016.
Bekker L-G, Laher F, Moodie Z, Tomaras G, Grunenberg N, Allen M, et al. Meeting the "Go'' criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. JOHN WILEY & SONS LTD; 2016.
Bekker, L. .. G., et al. “Meeting the "Go'' criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults.” JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 19, JOHN WILEY & SONS LTD, 2016.
Bekker L-G, Laher F, Moodie Z, Tomaras G, Grunenberg N, Allen M, Daniels B, Innes C, Mngadi K, Malahleha M, Gilbert P, Michael N, Phogat S, Granados CD, Kanesa-Thasan N, Corey L, Gray G, McElrath J. Meeting the "Go'' criteria: immunogenicity from HVTN100, a phase 1/2 randomized, double blind, placebo-controlled trial of clade C ALVAC-(R) (vCP2438) and Bivalent Subtype C gp120/MF59 (R) in HIV-uninfected South African adults. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. JOHN WILEY & SONS LTD; 2016.
Published In
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
EISSN
1758-2652
Publication Date
July 1, 2016
Volume
19
Publisher
JOHN WILEY & SONS LTD
Related Subject Headings
- 4206 Public health
- 4202 Epidemiology
- 3202 Clinical sciences
- 1199 Other Medical and Health Sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences